Late Clinical Outcomes of Percutaneous Mitral Commissurotomy in Patients With Mitral Stenosis

NCT ID: NCT04112108

Last Updated: 2019-10-02

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

220 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-03-01

Study Completion Date

2018-09-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In this retrospective cohort study, out of 220 patients who had undergone successful PTMC between 2006 and 2018, the clinical course of 186 patients could be successfully followed. Peri-procedural clinical and echocardiographic data were collected for these patients. Cardiac-related death, undergoing a second PTMC or mitral valve replacement (MVR) were considered adverse cardiac events in follow-up for the purpose of this study. Patients with no history of these events were contacted and asked to undergo echocardiographic imaging, in order to assess the prevalence of mitral valve restenosis, defined as mitral valve area (MVA) \< 1.5 cm2 and loss of ≥50% of initial area gain

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This research was designed as single-technique (Inoue balloon), multicenter retrospective- prospective cohort study. The target group of this study consisted of 220 patients with symptomatic MS who had undergone PTMC at in 4 hospitals (Baqiyatallah, Namazi, Shahid-Faghihi and Kowsar) under the supervision of Baqiyatallah University of Medical Sciences and Shiraz University of Medical Sciences between April 2006 and January 2018. The demographic data of the patients were obtained from the medical records departments at each center.

The inclusion criteria for the participants were: 1) age more than 20 years at the time of PTMC; 2) immediate post-PTMC mitral valve area (IMVA) ≥1.5 cm2, or for lower values, at least 50% increase in pre-PTMC mitral valve area (MVA); 3) an initial cardiovascular event-free period of at least 6 months after the procedure.

The exclusion criteria consisted of: 1) more than 2+ mitral regurgitation (MR) immediately after the procedure; 2) immediate cardiovascular event during the hospital stay after the procedure; 3) more than mild aortic stenosis or sufficiency before PTMC; 4) history of previous PTMC or surgical mitral procedures.

The study design and steps were approved by the ethics committees at both Baqiyatallah and Shiraz University of Medical Sciences.

PTMC Technique All PTMC procedures were done with an Inoue balloon catheter by skilled interventional cardiologists via anterograde trans-septal approach in all patients. Right and left cardiac catheterization was performed before and during the procedure to assess hemodynamic changes. Optimal balloon size (in millimeters) was estimated with the height (cm)/10 + 10 formula. The balloon was inflated in a step-wise fashion from lower to higher volumes. After each inflation, changes in trans-mitral mean pressure gradient (TMPG) and the degree of mitral regurgitation (MR) were monitored. Based on interventionist's judgement and in order to achieve optimal results, balloon inflation could be continued up to 1-2 mm more than the estimated size. In the last stage, left ventriculography was conducted to assess the degree of final MR.

Echocardiography All the patient included underwent transthoracic Doppler echocardiography (TTE) in the week before PTMC by expert cardiologists with an advanced echocardiography fellowship. All general echocardiographic findings and significant mitral valve-related characteristics were reported. MVA was measured by planimetry in the short axis view, and also by pressure half-time quantification when atrial fibrillation (AF) or MR were not serious enough to interfere with its interpretation. The degree of MR was reported on a semi-quantitative scale of 0 to 4 based on Doppler color flow mapping. Mitral valve morphology was also evaluated with the standard Wilkins echocardiographic scoring system in the spectrum of 4 to 16. Pulmonary arterial pressure was estimated by measuring systolic pulmonary arterial pressure (sPAP) in mmHg based on the trans-tricuspid regurgitation jet. Other significant variables in this study were left atrial diameter in centimeters, and mean trans-mitral pressure gradient (TMPG) in mmHg.

Each patient also had one session of transesophageal echocardiography during the day before the procedure in order to rule out thrombi in the left atrium or the left atrial appendage. Another session of TTE was performed during the first day after the procedure to confirm the immediate success of PTMC, with the main focus on mitral valve-related parameters, and also to rule out acute complications such as severe MR or cardiac tamponade.

Follow-up The clinical condition of the patients was recorded as their New York Heart Association (NYHA) functional class before the procedure. Their clinical status was also followed in their inpatient and outpatient records. For the purpose of this study, the patients or their first-degree relatives were contacted by telephone in order to record the occurrence and exact timing of any adverse cardiac events, and also to reassess their current NYHA functional class status. Clinical events considered significant for the purpose of this study included: 1) cardiac-related death, 2) another session of PTMC, or 3) surgical procedure of mitral valve replacement (MVR). Patients who had been event-free until that time were asked to undergo another TTE evaluation after providing their informed consent, in order to compare the echocardiographic variables noted above with their previous records.

Statistical Analysis Continuous variables are reported as the mean ± SD. Categorical and nominal variables are shown as the number and percentage, and were pooled in some cases in order to facilitate the interpretation of the results. Initially, univariate Cox proportional hazards regression analysis was used to assess the relationship between variables and adverse cardiac events at follow-up. In the next stage, Cox multivariable regression was also performed to single out the independent variables. To evaluate the variables for the occurrence of restenosis during follow-up, uni- and multivariate logistic regression analysis was used. Receiver operating characteristic (ROC) curves were generated to determine the best cut-off point for IMVA in interpreting the results. For all analyses a p-value of 0.05 or less was considered statistically significant. All data analyses were done with IBM SPSS Statistics version 23 software.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Mitral Valve Stenosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

OTHER

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

mitral stenosis post percutaneous mitral commissurotomy(PTMC)

successful PTMC after follow up

PTMC

Intervention Type PROCEDURE

percutaneous mitral ballooning with Inoue balloon

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PTMC

percutaneous mitral ballooning with Inoue balloon

Intervention Type PROCEDURE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

mitral ballooning

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* each patient with mitral stenosis undergone successful PTMC

Exclusion Criteria

* patient refuse to took part
* inability to follow patient
Minimum Eligible Age

35 Years

Maximum Eligible Age

52 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Baqiyatallah Medical Sciences University

OTHER

Sponsor Role collaborator

Shiraz University of Medical Sciences

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Javad Kojuri

Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Education Developmen Center

Shiraz, Fars, Iran

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Iran

References

Explore related publications, articles, or registry entries linked to this study.

Dadjo Y, Moshkani Farahani M, Nowshad R, Sadeghi Ghahrodi M, Moaref A, Kojuri J. Mid-term (up to 12 years) clinical and echocardiographic outcomes of percutaneous transvenous mitral commissurotomy in patients with rheumatic mitral stenosis. BMC Cardiovasc Disord. 2021 Jul 28;21(1):355. doi: 10.1186/s12872-021-02175-3.

Reference Type DERIVED
PMID: 34320949 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

97-55318

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Hyp Obst Cardiomyopathy
NCT04329689 UNKNOWN NA
The China Mviv Registry
NCT05925335 UNKNOWN NA
TAVR With Echocardiography Guidance
NCT07035847 RECRUITING NA